Tow

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

10/633,742

Inventor(s)

PETERS, Kevin G. et al.

Filed

August 4, 2003

Art Unit

1656

Examiner

NASHET, Nashaat T.

Docket No.

9045M

Confirmation No.

1253

Customer No.

27752

Title

HPTPbeta as a Target in Treatment of Angiogenesis

Mediated Disorders

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of document(s) which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited document(s) be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the document(s) listed on attached form PTO/SB08 is (are), or is (are) considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Authorization is hereby given to charge the fee set

Appl. No. 10/633,742 Docket No. 9045M Customer No. 27752 Paper dated 03 January, 2007

forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company.

## **ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

[X] In accordance with 37 C.F.R. §1.98(a)(2), copies of only foreign patent documents and non-patent literature are enclosed.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY

Signature

Andrew A. Paul

Typed or printed name Registration No. 46,405

(513) 622-1825

Date: 03 January, 2007 **Customer No. 27752** 

9045MIDS.doc

Appl. No. 10/633,742 Docket No. 9045M Customer No. 27752 Paper dated 03 January, 2007

# **INFORMATION DISCLOSURE STATEMENT**

## CO-PENDING AND/OR RELATED U.S. APPLICATIONS AND PATENTS

EXAMINER			DA	DATE CONSIDERED		
Examiners Initials	Application Serial Number 10/634,027	Application Filing Date (MM/DD/YYYY) August 4, 2003	Inventor(s) PETERS, Kevin G. et al.	Attorney Docket Number 9045M2	Patent or Publication Number, if published	Copy in IFW? Yes

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

#### Substitute for form 1449A/PTO COMPLETE IF KNOWN **Application Number** 10/633,742 Confirmation Number 1253 INFORMATION DISCLOSURE August 4, $200\overline{3}$ STATEMENT BY APPLICANT Filing Date (use as many sheets as necessary) First Named Inventor PETERS, Kevin G. **Group Art Unit** 1656 NASHED, Nashaat T. Examiner Name SHEET 1 of 1 9045M **Docket Number**

## U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	DOCUMENT NUMBER  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-			

### **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS*	Cite No.1	FOREIGN PATENT DOCUMENT  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Т°
		-				

### NON PATENT LITERATURE DOCUMENTS

EXAMINE R INITIALS*	Cite No.1					
	1	CHANTEAU, S.H. et al., "Synthesis of Anthropomorphic Molecules: The				
		NanoPutians," J. Org. Chem. 2003, Vol. 68, pp. 8750-8766.				
	2	HOPKINS, S.C. et al., "Inhibitors of Kinesin Activity from Structure-Based Computer				
	Screening," <u>Biochemistry</u> , 2000, Vol. 39, pp. 2805-2814.					
	3	JONES, G. et al., "Development and Validation of a Genetic Algorithm for Flexible				
	Docking," J. Mol. Biol. 1997, Vol. 267, pp. 727-748.					
	4	MARTIN, Y. C., "3D Database Searching in Drug Design," J. of Medicinal Chemistry,				
		1992, Vol. 35, No. 12, pp. 2145-2154.				
	5 RAREY, M. et al., "A Fast Flexible Docking Method Using An Incremental					
	Construction Algorithm," <u>J. Mol. Biol.</u> , 1996, Vol. 261, pp. 470-489.					
	6	SKOICHET, B.K. et al., "Lead Discovery Using Molecular Docking," Chem. Biology,				
	2002, Vol. 6, pp. 439-446.					
	7	STAHL, M. et al., "Detailed Analysis of Scoring Functions for Virtual Screening," J.				
		Med. Chem., 2001, Vol. 44, pp. 1035-1042.				
EXAMINE	R	DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 04/25/2006)